Finch Stock Analysis

FNCH -  USA Stock  

USD 13.17  1.01  7.12%

The current indifference towards the small price fluctuations of Finch Therapeutics could raise concerns from stockholders as the firm it trading at a share price of 13.17 on 26,700 in volume. The company executives did not add any value to Finch Therapeutics investors in July. However, most investors can still diversify their portfolios with Finch Therapeutics to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.66. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Finch Therapeutics partners.
Please check Investing Opportunities.

Search Stock Analysis 

The Finch Therapeutics stock analysis report makes it easy to digest most publicly released information about Finch Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Finch Stock analysis module also helps to analyze the Finch Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Finch Stock Analysis Notes

About 23.0% of the company shares are held by company insiders. The company had not issued any dividends in recent years. Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts. Finch Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 131 people. To learn more about Finch Therapeutics Group call the company at 617 229 6499 or check out

Finch Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Finch Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Finch Therapeutics Group or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Finch Therapeutics has very high historical volatility over the last 90 days
Finch Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 7.72 M. Net Loss for the year was (39.34 M) with loss before overhead, payroll, taxes, and interest of (25.43 M).
Finch Therapeutics has a poor financial position based on the latest SEC disclosures
About 23.0% of the company shares are held by company insiders
Latest headline from Finch Therapeutics Group Inc falls 7.12 percent for July 30 -

Finch Therapeutics Upcoming and Recent Events

Earnings reports are used by Finch Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Finch Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report12th of August 2021
Next Fiscal Quarter End30th of June 2021
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Finch Largest EPS Surprises

Earnings surprises can significantly impact Finch Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Finch Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Finch Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Finch Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Finch Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
13th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
27th of April 2021
Financial Statements and Exhibits. Regulation FD Disclosure. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
1st of April 2021
Unclassified Corporate Event
29th of March 2021
Unclassified Corporate Event
26th of March 2021
Unclassified Corporate Event
23rd of March 2021
Financial Statements and Exhibits. Other Events. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year

Finch Therapeutics Thematic Classifications

In addition to having Finch Therapeutics stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Pharmaceutical Products IdeaPharmaceutical Products
USA Equities from Pharmaceutical Products industry as classified by Fama & French

Finch Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 750.08 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Finch Therapeutics's market, we take the total number of its shares issued and multiply it by Finch Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Finch Profitablity

Finch Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Finch Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Finch Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Finch Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Finch Therapeutics' profitability requires more research than a typical breakdown of Finch Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.26) (0.28) 
Return on Average Equity 0.46  0.46 
Return on Invested Capital(0.96) (1.04) 
Return on Sales(5.10) (5.50) 

Management Efficiency

The entity has return on total asset (ROA) of (18.33) % which means that it has lost $18.33 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (35.61) %, meaning that it created substantial loss on money invested by shareholders. Finch Therapeutics management efficiency ratios could be used to measure how well finch therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return on Average Assets is estimated to decrease to -0.28. The current Return on Invested Capital is estimated to decrease to -1.04. Finch Therapeutics Assets Non Current are most likely to increase significantly in the upcoming years. The last year's value of Assets Non Current was reported at 59.17 Million. The current Tangible Assets Book Value per Share is estimated to increase to 18.14, while Total Assets are projected to decrease to roughly 164.9 M.
Last ReportedProjected for 2021
Book Value per Share(11.75) (12.68) 
Tangible Assets Book Value per Share 18.08  18.14 
Tangible Asset Value147.3 M144.9 M

Technical Drivers

As of the 1st of August, Finch Therapeutics shows the Mean Deviation of 3.09, coefficient of variation of 1888.9, and Downside Deviation of 5.08. Finch Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for Finch Therapeutics Group, which can be compared to its rivals. Please confirm Finch Therapeutics maximum drawdown, and the relationship between the information ratio and downside variance to decide if Finch Therapeutics is priced favorably, providing market reflects its regular price of 13.17 per share. Given that Finch Therapeutics has jensen alpha of 0.2574, we urge you to verify Finch Therapeutics Group's prevailing market performance to make sure the company can sustain itself at a future point.

Finch Therapeutics Price Movement Analysis

The output start index for this execution was fifty-nine with a total number of output elements of two. The Triangular Moving Average shows Finch Therapeutics double smoothed mean price over a specified number of previous prices (i.e., averaged twice). View also all equity analysis or get more info about triangular moving average overlap studies indicator.

Finch Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Finch Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Finch Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Finch Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Finch Therapeutics Predictive Daily Indicators

Finch Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Finch Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Finch Therapeutics Forecast Models

Finch Therapeutics time-series forecasting models is one of many Finch Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Finch Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Finch Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Finch Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Finch shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Finch Therapeutics. By using and applying Finch Stock analysis, traders can create a robust methodology for identifying Finch entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(4.99) (5.39) 
Gross Margin 1.00  1.09 
Profit Margin(5.10) (5.50) 
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts. Finch Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 131 people.

Current Finch Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Finch analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Finch analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
29.33Strong Buy3Odds
Finch Therapeutics Group current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Finch analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Finch stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Finch Therapeutics, talking to its executives and customers, or listening to Finch conference calls.
Finch Analyst Advice Details

Finch Stock Analysis Indicators

Finch Therapeutics Group stock analysis indicators help investors evaluate how Finch Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Finch Therapeutics shares will generate the highest return on investment. By understating and applying Finch Therapeutics stock analysis, traders can identify Finch Therapeutics position entry and exit signals to maximize returns.
Quick Ratio8.78
Fifty Two Week Low15.27
Float Shares5.21M
Fifty Two Week High22.50
Average Daily Volume Last 10 Day419.8k
Average Daily Volume In Three Month608.12k
Enterprise Value To Ebitda-3.37
Fifty Day Average16.98
Two Hundred Day Average16.98
Enterprise Value To Revenue16.90
Please check Investing Opportunities. Note that the Finch Therapeutics information on this page should be used as a complementary analysis to other Finch Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Finch Stock analysis

When running Finch Therapeutics price analysis, check to measure Finch Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Finch Therapeutics is operating at the current time. Most of Finch Therapeutics' value examination focuses on studying past and present price action to predict the probability of Finch Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Finch Therapeutics' price. Additionally, you may evaluate how the addition of Finch Therapeutics to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
The market value of Finch Therapeutics is measured differently than its book value, which is the value of Finch that is recorded on the company's balance sheet. Investors also form their own opinion of Finch Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Finch Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Finch Therapeutics' market value can be influenced by many factors that don't directly affect Finch Therapeutics underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Finch Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Finch Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Finch Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.